Please login to the form below

Not currently logged in
Email:
Password:

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

European Medicines Agency

The European Medicines Agency (EMA) has begun consulting on new guidelines for the development of medicines to treat Alzheimer's disease and other types of dementias.

The European regulator wants to address the impact of new diagnostic criteria on clinical trial design as well as the design of long term efficacy and safety studies.

Its plans also look at the need for assessment tools that cater to different disease stages and potential uses of biomarkers.

In a statement, the EMA said: “ Recent progress in understanding the pathophysiology of Alzheimer's disease suggest that the biological changes associated with the disease start to occur as early as 10 to 20 years prior to the emergence of clinical symptoms.

“Experimental medicines should therefore be evaluated in earlier disease stages as certain treatments many be more effective at that stage than later in the illness.”

The revised guidelines follow a November 2014 EMA workshop on the clinical investigation of Alzheimer's medicines, which introduced new diagnostic criteria for Alzheimer's disease.

Consequently early, and asymptomatic, disease stages and their impact in the make up of clinical trials for Alzheimer's drugs are also included in the EMA's revised guidelines.

The EMA considers dementia a key public health priority and has worked with patient representatives, regulators, the pharmaceutical industry and independent experts while compiling the draft guidelines.

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment has been slow.

Last year Roche and Evotec's sembragiline failed a phase II trial and Pfizer this week announced it has halted development of its candidate, PF-05212377, after it too failed to meet objectives in a phase II trial.

The consultation runs until 31 July 2016. For more information, see the EMA's draft Alzheimer's medicine research guideline

Article by
Dominic Tyer

4th February 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics